J.P.
Celgene Corporation (NASDAQ:CELG) has impending pipeline data on its way in 2H16, with the next few years anticipated to overflow with readouts of Phase …
At a recent dinner with brokerage firm Cowen, CFO Peter Kellogg and Inflammation & Immunology (I&I) President Scott Smith of Celgene Corporation (NASDAQ:CELG) …
Drug giant Celgene Corporation (NASDAQ:CELG) just came in strong this second quarter, thanks to great performances from pipeline drugs lymphoma treating Revlimid and Pomalyst, …
In a research report published Thursday, Piper Jaffray analyst Joshua Schimmer reiterated an Overweight rating on shares of Celgene Corporation (NASDAQ:CELG), with a price …
Celgene Corporation (NASDAQ:CELG) reported net product sales of $2,745 million for the second quarter of 2016, a 22 percent increase from the same period …
Celgene Corporation (NASDAQ:CELG) just released results from a phase 3, randomized, double-blind, international clinical REMARC study to investigate its pipeline drug Revlimid against a …
Analyst Brian Skorney from Baird discussed Gilead Sciences, Inc. (NASDAQ:GILD) and Celgene Corporation (NASDAQ:CELG) ahead of their second-quarter earnings reports.
Celgene Corporation (NASDAQ:CELG) announced that the European Commission (EC) has approved REVLIMID® (lenalidomide) for the treatment of adult patients with relapsed or refractory mantle …
